2021 IPO

Zymergen Stock

Biotechnology Company

Sign up today and learn more about Zymergen Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.



Notable Investors

Goldman Sachs


Emeryville CA, US

Total Funding


About Zymergen Stock

Zymergen researches, develops, and manufactures microbes for companies. It develops molecules for agriculture, chemicals, materials, pharmaceuticals, electronics, personal care, and more applications. Zymergen’s platform integrates automation, machine learning, and genomics to navigate the genomic search space. It uses a technology platform to optimize microbial strains that aims to improve economics of in-market products, existing production strains within existing manufacturing processes, and the correlation between the lab and commercial manufacturing. Moreover, Zymergen offers new product development, such as engineering any molecules from any microbes that improves the power of biology to develop novel products.

Jed Dean, Joshua J. Hoffman, and Zachary Serber founded the company in 2013, with headquarters in Emeryville in California and an additional office in Seattle in Washington.


Hanwha Asset Management

Zymergen, Health IQ

Linden Mobile Ventures


SoftBank Vision Fund

One97, WeWork, goPuff, OYO, Grab, Chime, DoorDash, Flexport, Rappi, Nuro

Trans-Pacific Technology Fund (TPTF)

Zymergen, Heal

Two Sigma

Zymergen, D2iQ

Funding History

June 2015$36.6M
June 2015$6.6M
October 2016$142M
November 2018$435M
July 2020$350M


Chief Executive Officer

Joshua Hoffman

Chief Technology Officer

Aaron Kimball


EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: